[1] Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med, 2017, 166:792-798.
[2] AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. Accessed December 11, 2017.
[3] European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017, 66: 153-194.
[4] Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology, 2018, 154: 989-997.
[5] Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med, 2016, 164:30-40. |
